Form 4: Roivant Director Ilan Oren Reports Share Transactions

Roivant Sciences Director Ilan Oren reported the acquisition of 1,507 common shares as an award and the disposition of 281 shares for tax withholding purposes.

Summary

• Ilan Oren, a Director of Roivant Sciences Ltd. (ROIV), reported transactions involving the company's common shares.
• On October 20, 2025, Oren acquired 1,507 common shares as an award under the Issuer's Non-Employee Director Compensation Plan.
• These acquired shares were fully vested as of the grant date and had a price of $0.
• Concurrently, Oren disposed of 281 common shares on October 20, 2025, at a price of $17.74 per share.
• This disposition represents a 'net settlement' by the Issuer to satisfy applicable tax withholding obligations related to the vesting and settlement of previously granted common shares.
• Following these transactions, Ilan Oren beneficially owns 118,388 common shares directly.

Sentiment

Score: 6

Explanation: Slightly positive due to a director receiving equity compensation, aligning interests, despite a small portion being sold for tax purposes which is a routine event.

Positives

• A Director, Ilan Oren, received an award of 1,507 common shares, indicating continued compensation and alignment with shareholder interests.
• The awarded shares were fully vested upon grant, providing immediate ownership.

Negatives

• A portion of shares (281) was disposed of to cover tax withholding obligations, reducing the net increase in beneficial ownership.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This is a routine insider transaction report (Form 4) detailing director compensation and tax-related share dispositions, which is common across all publicly traded companies and does not reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minor increase in director's beneficial ownership, aligning management interests with shareholders. The disposition for tax is a routine event and does not indicate a lack of confidence.

Key Dates

Keywords

Roivant Sciences, ROIV, Ilan Oren, Insider Transaction, Form 4, Director Compensation, Share Award, Tax Withholding, Beneficial Ownership